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Abstract In solid tumors, targeted treatments can lead to dramatic regressions, but responses are 
often short-lived because resistant cancer cells arise. The major strategy proposed for overcoming 
resistance is combination therapy. We present a mathematical model describing the evolutionary 
dynamics of lesions in response to treatment. We first studied 20 melanoma patients receiving 
vemurafenib. We then applied our model to an independent set of pancreatic, colorectal, and melanoma 
cancer patients with metastatic disease. We find that dual therapy results in long-term disease control 
for most patients, if there are no single mutations that cause cross-resistance to both drugs; in patients 
with large disease burden, triple therapy is needed. We also find that simultaneous therapy with two 
drugs is much more effective than sequential therapy. Our results provide realistic expectations for the 
efficacy of new drug combinations and inform the design of trials for new cancer therapeutics.
DOI: 10.7554/eLife.00747.001
Introduction
The current wave of excitement about targeted cancer therapy (Sawyers, 2004; Sequist et al., 2008; 
Kwak et al., 2010; Chapman et al., 2011; Gonzalez-Angulo et al., 2011) was initiated by the success 
of imatinib in the treatment of chronic myeloid leukemia (CML) (Druker et al., 2006; Gambacorti-
Passerini et al., 2011). Four decades of research passed between the discovery of the Philadelphia 
chromosome and the first treatment to target an activated oncogene in a human cancer. Targeted 
therapies against many different types of cancer are now being developed at a fast pace. These 
include gefitinib and erlotinib for non-small-cell lung cancer patients with EGFR mutations (Sequist et al., 
2008), panitumumab and cetuximab for metastatic colon cancer (Amado et al., 2008), vemurafenib 
for patients with melanomas harboring BRAF mutations (Chapman et al., 2011), and crizotinib for 
lung cancer patients with EML4-ALK translocations (Kwak et al., 2010). At present, dozens of other 
targeted cancer therapies have either been approved or are being evaluated in clinical trials.
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Although targeted agents have prolonged the lives of cancer patients, clinical responses are 
generally short-lived. In most patients with solid tumors, the cancer evolves to become resistant within 
a few months (Amado et al., 2008; Sequist et al., 2008; Gerber and Minna, 2010; Chapman et al., 
2011). Understanding the evolutionary dynamics of resistance in targeted cancer treatment is crucial 
for progress in this area and has been the focus of experimental (Engelman et al., 2007; Corcoran 
et al., 2010; Bivona et al., 2011; Diaz et al., 2012; Ellis et al., 2012; Misale et al., 2012; Straussman 
et al., 2012; Wilson et al., 2012; Khorashad et al., 2013) and theoretical studies (Dewanji et al., 
2005; Komarova and Wodarz, 2005; Michor et al., 2005, 2006; Haeno et al., 2007; Dingli et al., 
2008; Katouli and Komarova, 2010; Lenaerts et al., 2010; Beckman et al., 2012; Bozic et al., 
2012). One of the most important conclusions of these studies is that a small number of cells resistant 
to any targeted agent are always present in large solid tumors at the start of therapy and that these 
cells clonally expand once therapy is administered. Tumor recurrences are thus a fait accompli when 
single agents are delivered (Diaz et al., 2012).
How can one overcome the near-certainty of disease recurrence following therapy with such agents? 
Conceptually, there are two paths: treat tumors when they are very small, before a sufficient number 
of mutant cells conferring resistance have developed, or treat tumors with two or more drugs that 
target different pathways. In reality, the first option is usually not feasible, as clinicians have little or no 
control over the size of lesions in their patients at presentation. The second option, however, will 
become possible as more targeted agents are developed. The potential of combination therapy with 
targeted agents is buttressed by the success of conventional chemotherapeutic agents in leukemias 
and other cancers (DeVita, 1975) and of combination therapies for infectious diseases such as HIV 
(Porter et al., 2003). But the potential therapeutic utility of combination therapies targeting different 
pathways in solid tumors cannot be inferred from these prior studies, as the anatomic and evolutionary 
characteristics of solid tumors are far different from those of liquid tumors (leukemias) or infectious 
diseases. In this work, we have formulated a mathematical model to predict the effects of combined 
targeted therapies in realistic clinical scenarios and attempted to answer the question posed at the 
beginning of this paragraph.
eLife digest As medicine becomes increasingly personalized, more and more emphasis is being 
placed on the development of therapies that target specific cancer-causing mutations. But while 
many of these drugs are effective in the short term, and do extend patient lives, tumors tend to 
evolve resistance to them within a few months.
The key problem is that large tumors are genetically diverse. This means that for any given 
treatment, there is likely to be a small population of cells within the tumor that is resistant to the 
effects of the drug. When the drug is given to a patient, these cells will survive and multiply and this 
will lead ultimately to treatment failure. Given that a single drug is therefore highly unlikely to 
eradicate a tumor, combinations of two or more drugs may offer a higher chance of cure. This 
approach has been effective in the treatment of HIV as well as certain forms of leukemia.
Here, Bozic et al. present a mathematical model designed to predict the effects of combination 
targeted therapies on tumors, based on the data obtained from 20 melanoma (skin cancer) patients. 
Their model revealed that if even 1 of the 6.6 billion base pairs of DNA present in a human diploid 
cell has undergone a mutation that confers resistance to each of two drugs, treatment with those 
drugs will not lead to sustained improvement for the majority of patients. This confirms the need to 
develop drugs that target distinct pathways.
The model also reveals that combination therapy with two drugs given simultaneously is far more 
effective than sequential therapy where the drugs are used one after the other. Indeed, the model 
of Bozic et al. indicates that sequential treatment offers no chance of a cure, even when there are 
no cross-resistance mutations present, whereas combination therapy offers some hope of a cure, 
even in the presence of cross-resistance mutations.
By emphasizing the need to develop drugs that target distinct pathways, and to administer them 
in combination rather than sequentially, the study by Bozic et al. offers valuable advice for drug 
development and the design of clinical trials, as well as for clinical practice.
DOI: 10.7554/eLife.00747.002
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Results
Our model is based on a multitype branching process (see ‘Materials and methods’). Similar mathe-
matical modeling has successfully predicted the dynamics of acquired resistance, including the timing 
of treatment failure, in colorectal cancer patients treated with the EGFR inhibitor panitumumab (Diaz 
et al., 2012), and has led to specific recommendations for combination therapies to treat CML 
(Komarova et al., 2009; Katouli and Komarova, 2010). Our current work builds on these previous 
studies by using recent advances in the mathematical theory of branching processes (Antal and 
Krapivsky, 2011), which enable us to obtain results that are exact in the biologically relevant limit of 
many tumor cells and small mutation rate.
To obtain key parameters for our model, we have studied the dynamics of 68 index lesions in 
20 melanoma patients receiving the BRAF inhibitor vemurafenib. The data from six patients that 
represented distinct patterns of responses are shown in Figure 1. Patients P1 and P2 achieved com-
plete responses, and their lesions became undetectable. Patient P3 had stable disease, with tumors 
remaining approximately the same size throughout treatment. Patients P4 to P6 all had partial remis-
sions, with some lesions shrinking and others unchanging or regrowing during treatment. As expected, 
the smallest lesions were the ones most likely to become undetectable when the agent was 
effective.
For 21 lesions in our vemurafenib dataset, two pretreatment measurements were available. Using 
these data, we calculate the average net growth rate of these lesions to be 0.01 per day, which is 
consistent with previous reports (Friberg and Mattson, 1997; Eskelin et al., 2000). The estimated 
average time between cell divisions in the absence of cell death in melanoma cells is 7 days (Rew and 
Wilson, 2000), implying a birth (cell division) rate of b = 0.14 per day. We set this as the typical birth 
rate, and additionally explore birth rates that correspond to a wide range of 1–14 days between cell 
divisions (Supplementary file 3). To achieve the observed net growth rate, we set the cell death rate 
to d = b − 0.01 (typical d = 0.13). We assume that these birth and death rates are valid for all cell types 
prior to treatment. For simplicity, we assume that these birth and death rates remain constant for all 
cell types prior to treatment, and neglect variations in the growth rate due to spatial and metabolic 
constraints in solid tumors (Bozic et al., 2012).
A given cancer therapy will reduce the birth rate and/or increase the death rate of tumor cells. 
A cell type is defined as sensitive if the treatment in question would cause its death rate to exceed its 
birth rate; otherwise, it is resistant. The key parameters describing a particular combination treatment 
are its effects on the birth and death rates of cells and the number of point mutations that have 
the potential to confer resistance. Consider a treatment with two drugs, 1 and 2. We denote by n1 
(respectively, n2) the number of point mutations that have the potential to confer resistance to drug 1 
alone (respectively, drug 2 alone). We denote by n12 the number of point mutations that have the 
potential to confer resistance to both drug 1 and drug 2 (cross-resistance mutations). We assume that 
drugs in a combination treatment are given at concentrations tolerable by patients, and define the 
numbers of resistance mutations (n1, n2, n12) relative to these concentrations (Katouli and Komarova, 
2010).
A crucial quantity for the effects of combination therapy is the expected number, X, of resistant cells 
at the start of treatment in a lesion containing M cells. From the dynamics of our branching process 
model (see Supplementary file 1), we obtain
( )      
212
12 1 2 1 2 12
+ + + – .
2
n
X M n n n n n nμ μ≈
Here ( )= logu Ms
s
μ  (log denotes the natural logarithm), where s = 1 − d/b is the survival probability 
of the branching process initiated with a single cell and u is the point mutation rate, ∼10−9 for most 
cancers. As µ is small, this formula can be further simplified. If there is at least one possible mutation 
that could in principle confer resistance to both drugs, n12 ≥ 1, then X ≈ M n12 µ. In this case, the 
expected number of cells resistant to both drugs is independent of the numbers of mutations, n1 and 
n2, that have the potential to confer resistance to each individual drug. Intuitively, this means that 
tumor cells are much more likely to become resistant to dual therapy through the occurrence of one 
mutation conferring resistance to both drugs simultaneously than through sequential mutations con-
ferring resistance to each drug separately. If there is no mutation that could confer resistance to both 
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drugs simultaneously (no cross-resistance), then n12 = 0 and we obtain X ≈ M n1n2 µ2. This quantity 
scales with the square of the point mutation rate, so the number of resistant cells in a tumor will be 
much smaller than for the case n12 > 0. In general, the expected number of cells resistant to combination 
therapy with k drugs, with no cross-resistance, is X ≈ M n1n2 … nk µk (proof in Supplementary file 1).
We emphasize, however, that resistance is the outcome of random mutation, division, and death 
events, and consequently may arise in one lesion but not in another, even if these lesions are otherwise 
identical. We therefore also obtain formulas for the probability that resistance to combination therapy 
is present at the time of detection. This probability can be computed as res 1 2p =1– p p . Here, p1 is the 
probability that there is no resistance at detection that arose in a single mutational step, due to one of 
the n12 possible cross-resistance mutations. p2 is the probability that no such resistance arises in two 
A B
C D
E F
Figure 1. Variability in treatment response to monotherapy among six patients. Patients were treated with the 
BRAF inhibitor vemurafenib. Patients P1 and P2 achieved a complete response. Patient P3 had stable disease. 
Patients P4, P5, and P6 had partial responses. The minimal detection size (indicated by discontinuous red line) was 
assumed to be ≈63 × 106 cells.
DOI: 10.7554/eLife.00747.003
The following source data are available for figure 1:
Source data 1. Response to vemurafenib. 
DOI: 10.7554/eLife.00747.004
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mutational steps. These probabilities can be expressed as follows (proofs in Supplementary file 1, 
Section 4):
   1 12
log( )
p = exp
1–
s
Mun
s
 
≈   
2
2 1 2 12 1 2( ( ))
log( )log( )
p exp 2 + + .
(1– )
s Ms
Mu n n n n n
s s
As above, s = 1 − d/b is the survival probability of the branching process initiated with a single cell. 
The quantity 2n1n2 + n12(n1 + n2) in the expression for p2 represents the number of possible two-step 
mutational paths to dual resistance.
We turn now to the dynamics of the treatment response. Once treatment starts, sensitive cells 
decline, but resistant cells continue to grow. We assume that resistant cells maintain the pretreatment 
birth and death rates, b and d, respectively, during treatment. To obtain estimates for the birth rate b′ 
and death rate d′ of sensitive cells during treatment, we calculate that the 68 lesions in our dataset 
declined at median rate b′ − d′ = −0.03 per day (−0.01 and −0.07 being 10th and 90th percentile, 
respectively). Thus, we set the typical death rate of sensitive cells during treatment to d′ = b′ + 0.03, 
and additionally explore cases when treatment is less (d′ = b′ + 0.01) or more effective (d′ = b′ + 0.07). 
As a default in our simulations, we suppose that treatment affects only the death rate (b′ = b), but our 
mathematical analysis applies also to the case that treatment affects the birth rate.
A B C
FD E
Figure 2. Tumor response to mono and dual therapy. The tumor grows exponentially until a certain detection size, M, is reached, at which point 
treatment is initiated. The number of point mutations that could in principle confer resistance to monotherapy is n = 50. For dual therapy, the number of 
point mutations that could confer resistance to drugs 1 and 2 separately is given by n1 = 50 and n2 = 50. The number of point mutations that could 
confer resistance to both drugs simultaneously is given by n12. The point mutation rate was assumed to be u = 10−9 and the rate of cell division b = 0.14 
per day and is unaffected by treatment. The rate of cell death before treatment is d = 0.13 per day; it is increased to d’ for sensitive cells during 
treatment. (A)–(C) For clinically detectable sizes (M = 1010, 109, 108, depending on the location of the tumors and the detection methods used), mono-
therapy leads to a temporary shrinkage of the tumor but is always followed by tumor regrowth. (D) Due to stochastic fluctuations the few resistant cells 
present at the start of treatment go extinct and the lesion is eradicated. (E) Treatment leads to a temporary shrinkage of the tumor followed by regrowth. 
(F) The tumor decreases slowly in response to dual therapy, but resistant cells eventually evolve and cause treatment failure.
DOI: 10.7554/eLife.00747.005
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Figure 2 shows computer simulations of single lesions in response to targeted therapies. Previous 
studies (Engelman et al., 2007; Corcoran et al., 2010; Diaz et al., 2012; Ellis et al., 2012; Misale 
et al., 2012; Straussman et al., 2012; Wilson et al., 2012) suggest that about 50 different mutations 
can confer resistance to a typical targeted therapeutic agent. Assuming that there are 50 or more 
potential resistance mutations, monotherapy will eventually fail in all lesions that can be detected by 
conventional imaging (Figure 2A,B) even when the death rate d’ conferred by the therapy is far higher 
than usually observed in practice (Figure 2C). Small lesions, however, can decrease below the detec-
tion limit and appear to be eradicated for years before re-emerging (Figure 2B,C). This result is impor-
tant, as it explains why tumors can recur after long periods of remission without the need to invoke 
processes involving cancer stem cells, angiogenesis, or immune escape (Hensel et al., 2012). Note 
that results similar to those obtained by simulation are observed in several of the individual lesions 
from actual patients graphed in Figure 1.
The results predicted to occur with dual therapy are shown in Figure 2D–F. Here, we also assume 
that there are 50 mutations that have the potential to confer resistance to either drug alone, but also 
that there is at least one mutation that can confer resistance to both drugs simultaneously. Intuitively, 
one might imagine that the existence of even a single cell resistant to both drugs at the start of therapy 
will automatically result in treatment failure. However, our results show that this is not necessarily true, 
and that the response depends on the size of the lesion, the number of cross-resistant cells, and the 
effects of the therapy on the balance between cell birth and cell death. Three examples illustrate 
these points. In Figure 2D, there is a small number of cells resistant to both drugs at the initiation 
of dual therapy, but these cells are lost by stochastic drift and the lesion is eradicated. In Figure 2E, 
there is a greater, but still relatively small number (∼100), of cells resistant to both drugs. The lesion 
shrinks at first, but eventually progresses due to preexisting cross-resistance mutations within 
it. In the third lesion, the few cells resistant to both drugs at the initiation of therapy are lost 
to stochastic drift, but the cytolytic effects of the drug combination are less pronounced than in 
the other two cases (d’ = 0.15 instead of 0.17 or 0.21). The relatively slow decrease in lesion size 
enables the generation of de novo resistance mutations during treatment and the lesion eventually 
recurred (Figure 2F).
In summary, treatment failure can be caused either by the preexistence of resistance to both drugs 
in a small number of tumor cells (Figure 2E) or the emergence of resistant cells during treatment 
(Figure 2F). Taking both of these possibilities into account, the probability, eradp , that dual therapy 
eradicates a lesion containing M cells at the start of treatment is given by
↑ ↓ ↑ ↓
1 1 2 2eradp =p p p p . (1)
↑
1p  is the probability that no 1-step resistant lineage arises (and survives) prior to treatment. 
↓
1p  
is the probability that no 1-step resistant lineage arises (and survives) during treatment. ↑2p  is the 
probability that no 2-step resistant lineage arises (and survives) prior to treatment. ↓2p  is the prob-
ability that no 2-step resistant lineage arises (and survives) during treatment. Here, ‘steps’ refers 
to the number of mutations (one or two) needed to achieve dual resistance, and ‘lineage’ refers 
to the descendants of a single cell that has achieved dual resistance via a particular mutational 
path. The therapy is successful if there is no resistant lineage arising in any of these four scenarios; 
since these are independent events, the overall success probability is obtained by multiplying the 
corresponding probabilities as shown in equation (1). The probabilities that no 1-step resistant 
lineages arise before ( ↑
1p ) or during treatment (
↓
1p ) and survive are given by Komarova and Wodarz 
(2005)
↑
1 12p = exp(– )Mun
and Michor et al. (2006)
↓    1 12p =exp . '
s
Mun
s
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Here s = 1 − d/b as above, and s′ = 1 − d′ /b′, where b′ and d′ are birth and death rates of cells 
sensitive to at least one drug during treatment (note that s’<0). The probabilities that no 2-step 
resistant lineages arise before ( ↑
2p ) or during (
↓
2p ) treatment and survive can be calculated as:
( ) ( )
( ) ( )
 
 
↑        
    
' '
2
2 1 2 12 2 12' '
'
2 1 12 1 12 '
– 1 –
p =exp +  log + +
1 –
+ + log + +
s s s s
n n n u n n
sMss ss
s s
n n n u n n
Mu
sM ss
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( )( )↓    
2
2 1 2 12 1 2 2
p =exp – 2 + + .
'
s
Mu n n n n n
s
The proofs of these results are provided in Supplementary file 1, Section 5. Excellent agreement 
between equation (1) and simulation results is shown in Figure 3.
Although modeling of single neoplastic lesions is the norm in theoretical studies, most patients with 
advanced cancers have multiple lesions and curing a patient requires eradication of all lesions. 
Equation (1) can be used to evaluate which combination treatments will be successful in typical 
patients with multiple metastatic lesions.
To determine the total extent of disease in typical patients who enroll for clinical trials, we quantified 
all radiographically detectable metastases in 22 such patients: 7 with pancreatic ductal adenocarcinomas, 
11 with colorectal carcinomas, and 6 with melanomas—a different cohort than that depicted in Figure 1, 
in which only index lesions (those easiest to measure) were evaluated. The number of metastatic 
lesions in the 22 patients described in Table 1 ranged from 1 to 30, and their total tumor burden 
ranged from 9 × 108 to 3 × 1011 cells (see Supplementary file 2).
For each of these 22 patients, we used equation (1) to calculate the probability that monotherapy 
or dual therapy would eradicate all the patients’ lesions. We find that monotherapy will fail in all 
22 patients (Table 1 and Supplementary file 3), as expected from the simulations in Figure 2A–C and 
Figure 3. Probability of tumor eradication for two-drug combination therapy. A single mutation conferring cross-
resistance to both drugs (n12 = 1) can prohibit any hope for a successful dual therapy. Solid curves show analytical results for 
dual therapy and dashed curve shows analytical results for a typical monotherapy, both are calculated using equation (1). 
Markers (square, triangle, circle, diamond) indicate simulation results (averages of 106 runs). Parameter values: birth rate b 
= 0.14, death rate d = 0.13, death rate for sensitive cells during treatment d’ = 0.17, point mutation rate u = 10−9.
DOI: 10.7554/eLife.00747.006
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from clinical experience. If there is even one possible mutation that can in principle confer resistance 
to both drugs, then our model shows that dual therapy has also only a small chance of curing patients, 
even those with the smallest tumor burden. In our cohort of 22 patients, none are expected to be 
cured under these circumstances (Table 1). Only if there are no potential mutations that can confer 
cross-resistance will dual therapy be successful in eradicating all lesions. In the cohort described in 
Table 1, we calculate that eight patients (those with the smallest tumor burden) would have >95% 
probability of cure. Those with the largest tumor burden would still have a >20% probability of tumor 
recurrence. Additional simulations show that therapy with three agents will also not cure patients if 
there is even one mutation that can confer resistance to all three agents. Similar conclusions hold if we 
vary parameter values within a reasonable range (Supplementary file 3). We note that in patients 
whose tumors have high cell turnover (time between cell divisions of 1 day, corresponding to b = 1), 
even dual therapy with no cross-resistance mutations would be expected to fail in 37% of patients 
described in Table 1 (Supplementary file 3).
Graphical representations of the simulated responses of two patients with multiple metastatic 
lesions are shown in Figure 4. With monotherapy in patient N1 (Figure 4A), all lesions are predicted 
Table 1. Probability of treatment failure for combination therapy in patients
Patient
Primary  
tumor type
Number of 
metastases
Total  
tumor burden  
(number of cells)
Probability of treatment failure
Monotherapy
Dual  
therapy:  
n12 = 1
Dual  
therapy: 
n12 = 0
N1 Pancreas 18 2.6 × 1011 1 1 0.283
N2 Colon 25 2.3 × 1011 1 1 0.26
N3 Melanoma 26 1.7 × 1011 1 1 0.203
N4 Melanoma 30 1.4 × 1011 1 1 0.172
N5 Colon 21 1.0 × 1011 1 1 0.128
N6 Melanoma 8 9.8 × 1010 1 1 0.12
N7 Colon 25 9.1 × 1010 1 1 0.112
N8 Pancreas 8 7.4 × 1010 1 1 0.092
N9 Pancreas 23 6.4 × 1010 1 1 0.08
N10 Pancreas 5 5.5 × 1010 1 1 0.069
N11 Colon 14 5.4 × 1010 1 1 0.068
N12 Rectal 23 4.8 × 1010 1 1 0.061
N13 Melanoma 9 4.1 × 1010 1 1 0.052
N14 Pancreas 13 4.1 × 1010 1 1 0.051
N15 Pancreas 8 3.3 × 1010 1 1 0.042
N16 Melanoma 7 2.2 × 1010 1 1 0.028
N17 Melanoma 10 2.1 × 1010 1 1 0.027
N18 Colon 4 2.0 × 1010 1 1 0.026
N19 Melanoma 9 1.8 × 1010 1 1 0.023
N20 Colon 3 1.6 × 109 1 0.881 0.002
N21 Melanoma 21 1.3 × 109 1 0.828 0.002
N22 Pancreas 1 8.5 × 108 1 0.677 0.001
For monotherapy, we assume that 50 point mutations (n = 50) can in principle confer resistance to the drug. With 
dual therapy, we assume that 50 point mutations can in principle confer resistance to each drug individually  
(n1 = n2 = 50). Two scenarios are modeled: in the first, there is one mutation that can in principle confer resistance 
to both drugs (i.e., cross-resistance, n12 = 1). In the other case, there are no possible mutations that can confer 
resistance to both drugs (n12 = 0). Parameter values: birth rate, b = 0.14, death rate, d = 0.13, death rate for 
sensitive cells during treatment, d′ = 0.17, point mutation rate u = 10−9.
Colon: colonic adenocarcinoma; Rectal: rectal adenocarcinoma; Pancreas: pancreatic ductal adenocarcinoma.
DOI: 10.7554/eLife.00747.007
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to regress, but then recur within a year or so after the initiation of therapy (Figure 4B, left panel). 
Treatment failure in most lesions would also occur after dual therapy when there is at least one mutation 
that could confer resistance to both agents, although the length of remission will be longer than with 
monotherapy (Figure 4B, middle panel). In patient N11, with less disease burden, dual therapy will fail 
to eradicate several of the lesions when there is a possibility of a single cross-resistance mutation, but 
there is hope of cure if no such cross-resistance mutations are possible (Figure 4C,D).
In current clinical practice, it is common to administer targeted agents sequentially: once relapse occurs, 
a second, often experimental, agent is administered. The model described above can also be used to 
predict the relative effectiveness of sequential vs simultaneous therapies of a single lesion with two drugs. 
When there is a possibility of a single mutation conferring resistance to both drugs, sequential combination 
therapy will ‘always’ fail. In ∼74% of lesions, the failure is due to mutations that were present prior to the 
treatment with the first drug, whereas in ∼26% of the lesions, failure is due to the development of cells 
resistant to drug 2 during treatment with drug 1 (Figure 5A and Figure 5—figure supplement 1). With 
simultaneous treatment, it is possible to eradicate ∼26% of the lesions even when cross-resistance muta-
tions are possible (Figure 5B). When there is no possibility of a mutation conferring cross-resistance to 
A
B
C
D
Figure 4. Treatment response dynamics to monotherapy and dual therapy in two patients. (A) Depiction of all 
18 detectable metastases in patient N1, who had a particularly heavy tumor burden (scale 1:4). (B) Simulated 
treatment of patient N1, comparing monotherapy with n = 50 resistance mutations and dual therapy with 
n1 = n2 = 50 resistance mutations to the individual drugs and one (n12 = 1) or no (n12 = 0) cross-resistance 
mutations to both drugs. (C) Depiction of all 14 detectable metastases in patient N11, who had a more typical 
tumor burden (scale 1:4). (D) Simulated treatment of patient N11. Parameter values for simulations in (B) and 
(D): birth rate b = 0.14; death rate d = 0.13; death rate for sensitive cells during treatment d′ = 0.17; point 
mutation rate u = 10−9.
DOI: 10.7554/eLife.00747.008
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both drugs, the differences are even more striking: sequential therapy fails in 100% of cases (Figure 5C), 
whereas simultaneous therapy succeeds in >99% of lesions of the identical size (Figure 5D).
One of the most important aspects of the cancer stem cell hypothesis revolves around therapeutic 
resistance. Evidence to date does not indicate that cancer stem cells are innately resistant to either 
single drugs or drug combinations. However, the precise proportion of cancer stem cells (among all 
cancer cells) has a dramatic effect on the development of resistance. This effect can be studied using 
our model if we use the number of cancer stem cells as an effective population size in our formulas and 
adjust other parameters to account for the stem cell dynamics (Tomasetti and Levy, 2010) (i.e., the 
birth rate should correspond to the rate of symmetric renewal, the rate of symmetric differentiation 
should be added to the death rate, and an effective mutation rate for stem cells should be introduced 
to account for mutations that occur during asymmetric division). For example, if cancer stem cells rep-
resent only 0.1% of cancer cells, then the development of resistance to single agents or combinations 
is roughly 0.1% as likely as if 100% of the cancer cells have the capacity to repopulate the tumor. The 
fraction of cancer stem cells appears to be this low in CML, perhaps explaining the remarkable success 
of imatinib (Michor et al., 2005). In solid tumors, however, the fraction of cancer stem cells seems 
much higher, usually higher than 5% and in some cases close to 100% (Shackleton et al., 2009). This 
issue is further complicated by the fact that the situation is plastic, with non-stem cells converting to 
cancer stem cells under certain conditions (Gupta et al., 2009). As better approaches to quantify 
A B
C D
Figure 5. Sequential vs simultaneous therapy with two drugs. (A) If there is even a single mutation that confers 
cross-resistance to both drugs (n12 = 1), then sequential therapy will fail in all cases. In 73.7% of the cases, this failure 
is due to the exponential growth of fully resistant cells that were present at the start of treatment. In the remaining 
26.3% of cases, the failure is due to resistance mutations that developed during therapy with the first drug. (B) With 
simultaneous therapy, 26.3% of patients can be cured under the same circumstances. In the remaining patients 
(73.7%), cross-resistant mutations existed prior to the therapy and their expansive growth will ensure treatment 
failure whether treatment is simultaneous or sequential (see  Figure 5—figure supplement 1 for further details). 
(C) and (D) If the two drugs have no resistance mutations in common (n12 = 0), then simultaneous therapy is 
successful with a probability of 99.9% while sequential therapy still fails in all cases.
DOI: 10.7554/eLife.00747.009
The following figure supplements are available for figure 5:
Figure supplement 1. Examples for the evolution of resistance during sequential therapy. 
DOI: 10.7554/eLife.00747.010
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cancer stem cells in solid tumors become available, our estimates of the likelihood of therapeutic 
success will be improved.
If resistance has a fitness cost, then we expect a smaller number of resistant cells at the start of 
treatment and correspondingly a higher chance of treatment success. We used computer simulations 
to verify our results in the case when there is a cost for resistance, by assuming that each resistance 
mutation decreases the net growth rate of the cell by up to 10%. The results are shown in Table 2. For 
combination therapies with drugs that have resistance mutations in common, the probability of 
eradicating a lesion is only marginally affected by costly resistance. For dual therapies with no cross-
resistance mutations, treatment has a high chance of eradicating all but the largest lesions, whether or 
not resistance is costly. In the case of large lesions with high cell turnover rates (the case in which even 
dual therapies with no cross-resistance might fail), costly resistance increases the chance of treatment 
success. For example, if each resistance mutation decreases the net growth rate of cells by 10%, the 
probability that dual therapy with no cross-resistance mutations will eradicate a lesion of size 1011 in 
which cells divide on average every day is 68% (compared with 47% in the case of neutral resistance).
Some therapies may directly eliminate tumor cells (d′ > d), whereas others may impede their 
division (b′ < b). Our formulas account for both of these possibilities. Overall, the rate b′ − d′ of tumor 
decline is of primary importance, and whether this is achieved by eliminating cells or suppressing division 
has only a minor effect on treatment outcomes. For example, consider a dual therapy with n1 = n2 = 50, 
n12 = 1, applied to a lesion of size M = 109, with other parameters as inferred from our dataset. If this 
therapy shrinks the tumor at rate −0.03 per day by increasing cell death, the eradication probability is 
26%. If the therapy instead suppresses division, this probability increases to 29%, because there are 
fewer chances for resistance mutations during treatment.
While our typical parameter values are derived from the melanoma dataset, our analytical results 
can accommodate parameter values from any other type of cancer, once they become available. 
Furthermore, our results are qualitatively robust across a wide range of birth and death rates 
(Supplementary file 3). The parameters with the strongest effects on the success of combination 
treatments—apart from the number of cross-resistance mutations—are lesion sizes and point mutation 
rate. Thus, we expect that combination treatments will be more effective in cancers with small fractions 
of tumor stem cells (small effective population size of lesions) and less effective in cancers with 
significantly increased point mutation rates.
Discussion
Our conclusions are highly relevant for the expanding development and use of targeted agents for 
cancer therapy. Most importantly, they show that even if there is one genetic alteration within any of 
the 6.6 billion base pairs present in a human diploid cell that can confer resistance to two targeted 
agents, therapy with those agents will not result in sustained benefit for the majority of patients with 
advanced disease. The same result is obtained with triple therapy; if there is the possibility of a mutation 
Table 2. Simulation results for the probability of treatment failure when resistance is costly
Dual therapy: Number  
of cells Birth rate
Probability of treatment failure
n1 = n2 n12 c = 0% c = 1% c = 5% c = 10%
50 0 109 0.14 0.0 0.0 0.0 0.0
50 0 109 1 0.01 0.01 0.01 0.0
50 1 109 0.14 0.74 0.73 0.72 0.7
50 1 109 1 0.74 0.74 0.72 0.7
50 0 1011 0.14 0.12 0.11 0.08 0.06
50 0 1011 1 0.53 0.51 0.42 0.32
50 1 1011 0.14 1.0 1.0 1.0 1.0
50 1 1011 1 1.0 1.0 1.0 1.0
Each resistance mutation reduces the net growth rate by a factor c via a decrease of the birth rate b. Parameter 
values are death rate, d = b − 0.01, death rate for sensitive cells during treatment, d’ = b + 0.03, point mutation 
rate, u = 10−9. The simulation results are averages over 106 runs per parameter combination.
DOI: 10.7554/eLife.00747.011
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conferring cross-resistance to three drugs, lesions of the size commonly observed in patients with 
advanced cancers will always recur. Similar conclusions were reached by Komarova et al. (2009), who 
showed that a combination of three current targeted drugs for CML will not be beneficial over a 
combination of two such drugs due to cross-resistance. Our formulas could be used to develop an 
optimum in vitro assay to detect the existence of cross-resistance mutations for a given drug 
combination.
The development of drugs that act through distinct pathways will therefore be essential for the 
success of combination therapies in the clinic. Although this seems feasible in principle, there are a 
number of observations suggesting that it will be difficult in practice. For example, it has been shown 
that the increased expression of growth factors (such as hepatocyte growth factor) can confer resistance 
to a variety of drugs that inhibit kinases functioning through different pathways (Straussman et al., 
2012; Wilson et al., 2012). Moreover, it is well known that mutations in several different genes, 
including those encoding ABC transporters, can confer resistance to many different drugs (Lavi et al., 
2012). Drugs that have very different chemical structures, in addition to distinct mechanisms of action, 
may be required to circumvent these resistance mechanisms.
Our results are not readily applicable to therapies that rely on the immune destruction of tumors 
(Kirkwood et al., 2012), such as those employing CTLA-4 (Hodi et al., 2010), PD1 (Topalian et al., 
2012), or CD19-CARs (Grupp et al., 2013). This promising line of therapy relies on an ongoing battle 
between cancer cells and the immune system. The immune system, unlike small molecule compounds, 
can replicate and evolve, and the factors underlying therapeutic success or failure are not sufficiently 
understood to allow useful modeling at this point. Once the mechanisms underlying the failures of 
immune modulators become more apparent, it will be important to try to understand why long-term 
control of disease is more common with these therapies than with small molecule drugs.
Our results on sequential vs simultaneous therapy with two or more agents (Figure 5) are in agreement 
with previous results (Katouli and Komarova, 2011) and have immediate practical implications even while 
new combinations are being developed. Sequential administration of targeted agents is often used to 
treat patients, for a variety of medical and economic reasons. Our data show that this sequential 
administration precludes any chance for cure—even when there are no possible mutations that can confer 
cross-resistance (Figure 5C). And when there are potential mutations conferring cross-resistance to 
two or more agents, simultaneous administration offers some hope for cure while there is no hope with 
sequential therapy (Figure 5A). The realization of the advantages of simultaneous vs sequential dual 
therapy will hopefully stimulate efforts to combine agents much earlier in the drug development process.
Materials and methods
Model
We model tumor growth and evolution as a continuous time multitype branching process (Athreya and 
Ney, 1972; Goldie and Coldman, 1998; Komarova and Wodarz, 2005). In the case of two drugs, 
there are four possible types: 00, 01, 10, and 11, where zeros indicate sensitivity to a drug and ones 
indicate resistance. For example, type 01 is sensitive to drug 1 and resistant to drug 2.
Our model includes two phases: pretreatment and treatment. The pretreatment phase is initiated 
with a single fully sensitive cell (type 00 for two drugs). During this phase, all cell types reproduce at 
rate b and die at rate d. The offspring of a type 00 cell has probability un1 of being type 10, un2 of 
being type 01, un12 of being type 11, and otherwise is of type 00. The offspring of a type 10 cell has 
probability u (n2 + n12) of being of type 11 and otherwise is of type 10; similar probabilities apply to 
type 01. Type 11 cells produce only type 11. These formulas generalize in straightforward manner to 
combination therapy with three or more drugs.
The pretreatment phase ends, and the treatment phase begins, when there are a total of M cells. 
During the treatment phase, all cell types that are sensitive to one or more drugs have birth rate b’ and 
death rate d’; fully resistant cells maintain the pretreatment birth and death rates. Mutation probabilities 
are unchanged.
Analysis
Our mathematical analysis of dual therapy is based in part on a recently discovered exact solution to 
the two-type branching process (Antal and Krapivsky, 2011). Detailed proofs of all results are pro-
vided in Supplementary file 1.
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Computer simulations
We use Monte Carlo computer simulations to confirm our analytical results and improve our under-
standing of the evolutionary dynamics during cancer treatment. The developed tool is an enhanced 
version of TTP (Tool for Tumor Progression) where the discrete time branching processes are replaced 
by continuous time branching processes (Reiter et al., 2013). Moreover, the new version also simu-
lates tumor dynamics during treatment with several drugs. The simulations implement a multitype 
birth–death branching process using the specified parameter values. For cell subpopulations with less 
than 104 cells, the process is simulated exactly; for larger subpopulations, a deterministic (exponential 
growth) approximation is used in the interest of efficiency. Within this deterministic approximation, the 
timing of appearances of new mutations is simulated using an adapted version of the Gillespie algo-
rithm (Gillespie, 1977). Between 106 and 108 runs are used for each parameter combination.
To study the consequences of costly resistance, we suppose that each resistance mutation reduces 
the cell division rate such that the net growth rate is decreased by a factor c representing the metabolic 
costs of resistance. For example, cells with two resistance mutations divide at rate (b − d)(1 − c)2 + d.
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